Segmentation and Forecast of Global Oncology/Cancer Drugs Market, 2013 - 2020
- Written by: Pitch Engine
The global oncology drugs market is expected to reach at $111.9 billion by 2020. Patent expiration of key cancer drugs such as Herceptin, Erbitux, Rituxan and Avastin, is expected to boost the growth of cancer biosimilars market by 2020. Going further, the biological therapies are expected to dominate the market by 2020, due to their high efficacy, target specific action and less toxicity. Blood cancer drugs market was the largest revenue generating segment in 2013 owing to the high cost of drugs (immunotherapies) used for the treatment of blood cancer.
Geographically, North America, dominates the market followed by Europe. North America accounted for about ~38% share in the overall oncology drugs market in 2013 owing to the heavy investments by multinational companies in research and development of cancer drugs, particularly immune therapeutics, favorable reimbursement policies, and high adoption rate of immunotherapies. On the other hand, Asia-Pacific market would grow at the promising CAGR of 8.7% during the forecast period. Such high growth rate is majorly due to increasing awareness towards advanced therapies namely immunotherapies and increase in per capita healthcare spending.
The report provides the quantitative analysis of the current market and estimations through 2013-2020 that assists in identifying the prevailing market opportunities to capitalize onThe report helps in understanding the strategies adopted by various companies for gaining market share in the cancer drugs marketThe report provides comprehensive analysis of factors that drive and restrict the growth of the cancer drugs marketMarket conditions of cancer drugs market across all geographic regions are comprehensively analyzedCompetitive intelligence (of leading manufacturers) helps in understanding the competitive scenario across the geographiesSWOT analysis of the key market players is provided to illustrate the business strategies adopted by the companiesMARKET SEGMENTATIONThe cancer drugs market is segmented by the therapeutic modalities, cancer types and geography.
MARKET BY THERAPEUTIC MODALITIESChemotherapyTargeted TherapyImmunotherapy (Biologic Therapy)Hormonal TherapyOthersMARKET BY CANCER TYPESBlood CancerBreast CancerGastrointestinal CancerProstate CancerRespiratory/Lung CancerSkin CancerOther CancersMARKET BY GEOGRAPHY
North AmericaUnited StatesCanadaMexicoEuropeGermanyFranceUnited KingdomOthersAsia-PacificIndiaChinaJapanAustraliaOthersLAMEAGCC (Gulf Corporation Council)Others
Companies Mentioned
Amgen Inc., Johnson and Johnson, Roche Diagnostics, GlaxoSmithKline PLC, Merck & Company, Novartis AG, Pfizer, Sanofi, Eli Lilly and Company, Celgene Corporation
Contact:
Debora White
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research
Authors: Pitch Engine
Read more http://www.pitchengine.com/pitches/16c14321-4ea0-4cbc-86e8-13dc455583f8
Daily Bulletin
